This mechanism may be employed for future cancer therapies aiming to induce a specific immune reaction, a reduced tumour-load, and a long-lasting anti-tumour immunity by combining standard therapies with the application of exogenous AnxA5. This evidence concerns the gene ANXA5 and neoplasm.